Related Experiment Videos
Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a
F Al-Azzawi1, M Wahab, J Thompson
1Department of Obstetrics and Gynaecology, Leicester Royal Infirmary, UK.
Human Reproduction (Oxford, England)
|April 30, 1999
Summary
Higher doses of trimegestone in hormone replacement therapy led to lighter, shorter uterine bleeding. Menopausal symptom control was effective across all doses with minimal side effects.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
Background:
- Trimegestone, a norpregnane progestogen, is under development for postmenopausal hormone replacement therapy (HRT).
- Combination therapy with oral oestradiol is being investigated.
Purpose of the Study:
- To evaluate dose-ranging effects of trimegestone in combination with oestradiol for HRT.
- To assess uterine bleeding patterns, endometrial histology, and menopausal symptom control.
Main Methods:
- Multicentre, randomized, parallel-group study.
- 203 women received micronized oestradiol (2 mg/day) with one of four sequential trimegestone doses (days 15-28) for 6 months.
Main Results:
- Higher trimegestone doses correlated with later onset, lighter, and shorter uterine bleeding.
- Bleeding onset variability was greater in early bleeders compared to late bleeders.
- All women reported good control of menopausal symptoms with minimal progestogenic adverse effects, with no significant dose-group differences.
Conclusions:
- Trimegestone dosage influences uterine bleeding patterns in sequential HRT.
- Effective menopausal symptom management and tolerability were observed across tested trimegestone doses.